
News|Articles|February 13, 2019
Talzenna for gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer
Author(s)Drew Boxler
Advertisement
Talzenna (talazoparib, Pfizer)
Indications: Adult Patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.
Dosage: 1 mg singly oral daily dose until disease progression or unacceptable toxicity occurs
Contraindications: None
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Reaffirms Strict Regulations Amid GLP-1 Compounding Concerns
2
Bipartisan Legislation Aims to Address Consolidation and Vertical Integration of PBMs
3
Tryptyr Increases Tear Production in Dry Eye Disease
4
Cigna to Remedy Years of Unfair Business Practices with Patients and Pharmacies
5




































